Home > Boards > US Listed > Biotechs >

Mast Therapeutics, Inc. (MSTX)

Add MSTX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator LaJollaCA, Rhodey Red
Search This Board:
Last Post: 7/23/2014 10:40:54 AM - Followers: 308 - Board type: Free - Posts Today: 0

Mast Therapeutics
 We are a publicly traded biopharmaceutical company headquartered in San Diego, California.

We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, our lead product candidate, for serious or life-threatening diseases with significant unmet needs.

http://wsw.com/webcast/cowen16/MSTX/  Webcast from Cowen Healthcare Conference 03/03/14


http://www.media-server.com/m/p/to9vgb8uhttp://www.media-server.com/m/p/to9vgb8u  Piper Jaffray Healthcare Conference 12/03/13 : 30 minute audio presentation by CEO B. Culley  NEW

http://www.masttherapeutics.com/wp-content/uploads/2012/09/MastThera_CorpPres_10.08.2013.pdf    12th Annual Bio-Investor Conference 10/08/13: 32 page PDF NEW

Blog Update from CEO B. Culley 12/12/13  NEW

http://www.masttherapeutics.com/investors/news/?releaseid=1887966  Data From Proof of Concept Study in Heart Failure 


A service of the U.S. National Institutes of Health


  • Make bi


Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC)

This study is currently recruiting participants.
Verified July 2013 by Mast Therapeutics, Inc.
Mast Therapeutics, Inc.
Information provided by (Responsible Party):
Mast Therapeutics, Inc.
ClinicalTrials.gov Identifier:
First received: November 27, 2012
Last updated: July 22, 2013
Last verified: July 2013

The purpose of this study is to evaluate whether ANX-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether ANX-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive ANX-188 to those who do not receive ANX-188.

Condition Intervention Phase
Vaso-occlusive Crisis
Sickle Cell Disease
Drug: ANX-188
Drug: Saline
Phase 3
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ANX-188 (Purified Poloxamer 188) Injection in Children With Sickle Cell Disease Experiencing Vaso Occlusive Crisis
Resource links provided by NLM:
Further study details as provided by Mast Therapeutics, Inc.:
Primary Outcome Measures:
  • Reduction of the duration of vaso occlusive crisis (VOC) in subjects with sickle cell disease. [ Time Frame: Study participants will be followed for the duration of hospital stay, an expected average of 4 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Re-hospitalization rate for VOC [ Time Frame: Hospital discharge to 14 days post-discharge ] [ Designated as safety issue: No ]
    Occurence of acute chest syndrome [ Time Frame: Randomization to 120 hours after randomization ] [ Designated as safety issue: No ]
Estimated Enrollment: 388
Study Start Date: May 2013
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ANX-188
ANX-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
Drug: ANX-188
Placebo Comparator: Saline
Saline administered as a continuous infusion for up to 49 hours
Drug: Saline


Please refer to this study by its ClinicalTrials.gov identifier: NCT01737814

Contact: Mast Therapeutics CT.gov Call Center 1-888-965-1238  

Responsible Party: Mast Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01737814     History of Changes
Other Study ID Numbers: ANX-188-01
Study First Received: November 27, 2012
Last Updated: July 22, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Mast Therapeutics, Inc.:
sickle cell disease
vaso-occlusive crisis

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on July 25, 2013





MST-188 (lead product candidate)

MST-188 (purified poloxamer 188) is an investigational agent that has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. We initially are developing MST-188 as a treatment for complications arising from sickle cell disease.



Exelbine™, or ANX-530 (vinorelbine injectable emulsion), is a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine®). We are seeking a partner or outside investor to continue development of the Exelbine program.


ANX-514 (docetaxel for injectable emulsion) is a novel, detergent-free emulsion formulation of the chemotherapy drug docetaxel. We are seeking a partner or outside investor to continue development of the ANX-514 program.

2013 Activities

Event Timing

Initiate tQT/QTc Study Completed

Secure Orphan Designation for MST-188 for SCD in EU Completed

Activate First Site in Phase 3 Study Completed

File New Patent Applications Completed

Dose First Subject in Phase 3 Study Completed

Report data from tQT/QTc Study Q3 Completed and Primary Endpoints Met

Request Orphan Designation for MST-188 for ALI in U.S. Q3 Completed and Designation Granted By FDA

Initiate Nonclinical Proof-of-Concept Study in Heart Failure Q3 Completed and POC Data to be released Q1 '14

2014 Activities

Event Timing

Present Data From Nonclinical Proof-of-Concept Study In Heart Failure  Q1 '14  Data Released 01/06/14'Showed Significant Statistical Improvement"

Initiate Phase 2 Study in ALI Q1 '14 Initiated

Outcome of review of application for Unique Name Designation For Purified Poloxamer 188 From U.S. Adopted Names Counsel Q1 '14 Granted and Named VEPOLOXAMER

Open First Ex-U.S. Clinical Sites in Phase 3 Trial Q1 '14. Initiated and On Schedule

Submit Abstract with Heart Failure Study Biomarker Data to Major Medical Conference Q2 '14

Request Orphan Designation for ALI in EU Q2 '14  Application Submitted

Initiate Nonclinical POC Study in Stroke Q2 '14 Study Initiated

Initiate EPIC Sub-Study Q2 '14 Initiated On Schedule 06/14/14

Report Results from Phase 2 Study of AIR001 in PAH Q3 '14

Initiate study with Dept of Defense: MST-188 Resuscitation from major trauma '14


Video of Management of Mast Therapeutics $MSTX speaking about MST-188 for Sickle Cell Disease ,orphan drug 






Schedule 13D and 13G filings submitted since 03/31/2013

  Filing Company Date of
Total Reported
Shares Owned
Shares Reported
on 13F
SC 13G GREAT POINT PARTNERS LLC 09/30/2013 8,700,000 5,442,400
SC 13G SABBY MANAGEMENT, LLC 01/14/2014 4,105,500 3,639,571
SC 13G FRANKLIN RESOURCES INC 07/10/2013 10,987,000 12,046,100
Reported via Event Date Name Ticker Shares * Change % of Portfolio
13F 2013-03-31 MAST THERAPEUTICS INC MSTX 875,000 New 0.11
13F 2013-06-30 MAST THERAPEUTICS INC MSTX 1,848,045 973,045 0.14







Contact Information

P: 858-552-0866    F: 858-552-0876
General Inquiries

Investor Relations Contact

Business Development Contact

Careers Contact




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ANX News: Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial 06/16/2014 08:00:00 AM
ANX News: Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease 04/14/2014 08:00:00 AM
ANX News: Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc. 02/10/2014 08:00:00 AM
#12220   No just bought almost 40k shares Dara. Stay akamaii 07/23/14 10:40:54 AM
#12219   Don't you ever get bored? The Sliver Man 07/23/14 10:39:14 AM
#12218   Target today 62 and officially new uptrend as akamaii 07/23/14 09:15:16 AM
#12217   Well, I know one that has a cancer akamaii 07/22/14 11:52:59 AM
#12216   Yeah, nice! I like this one for a akamaii 07/22/14 11:49:22 AM
#12215   This stock should already be at least $2.50 The Sliver Man 07/22/14 11:47:43 AM
#12214   I like MSTX under .60. I think HHHG 07/22/14 11:41:46 AM
#12213   http://www.nasdaq.com/quotes/institutional-portfolio/baker-bros-advisors-lp-5962 akamaii 07/22/14 08:14:30 AM
#12212   Bought 96k myself anything you want to share akamaii 07/21/14 12:43:23 PM
#12211   I've been hearing that for years around here. The Sliver Man 07/21/14 11:57:16 AM
#12210   Someone has bought around 200k shares plus this akamaii 07/21/14 10:46:46 AM
#12209   Thanks for your feeback. I agree that it The Sliver Man 07/17/14 12:43:55 PM
#12208   I found the content of the CEO blog Rhodey Red 07/17/14 08:41:42 AM
#12207   What are your thoughts on the content? The Sliver Man 07/17/14 03:46:04 AM
#12206   New CEO Blog uploaded today!!http://masttherapeutics.com/company/ceo-blog/ Rhodey Red 07/16/14 08:15:53 PM
#12205   Haha based on what a coin flip? okaly 07/16/14 05:55:57 PM
#12204   Im out for now sedrik 07/16/14 02:23:19 PM
#12203   Well yes, if you want to be pedantic. The Sliver Man 07/16/14 09:06:49 AM
#12202   Wrong .... It goes down. pray 07/16/14 08:29:38 AM
#12201   You should know by now, this never goes The Sliver Man 07/16/14 07:38:06 AM
#12200   So as I predicted, and you denied, this The Sliver Man 07/16/14 07:36:00 AM
#12199   Should not said anything about being up a pray 07/16/14 12:39:05 AM
#12198   Sad, Baxter had doubled in shareholder price in pray 07/15/14 09:24:10 AM
#12197   Hi what mean this email Im new sedrik 07/15/14 09:23:55 AM
#12196   Recent email correspondence with MAST CFO: Rhodey Red 07/14/14 07:57:06 PM
#12195   MSTX IN EUROPE STUTGART IS UP 10% today sedrik 07/14/14 09:35:29 AM
#12194   Price objective .80 Shaka_Zulu 07/14/14 08:36:55 AM
#12193   http://www.handelsblatt.com/unternehmen/industrie/pharmakonzern-merck-streckt-fu hbrandne 07/12/14 02:02:50 PM
#12192   Seems like MSTX is waiting in pre launch mode. $MSTX$ EZirish 07/11/14 04:38:11 PM
#12191   CHEAP BUY MORE sedrik 07/11/14 09:40:25 AM
#12190   Mast Therapeutics' MST-188 Would Fit Well In Merck's sedrik 07/11/14 09:40:05 AM
#12189   •Acquiring Mast Therapeutics would provide Merck with a sedrik 07/10/14 01:14:46 PM
#12188   Mast Therapeutics' MST-188 Would Fit Well In Merck's sedrik 07/10/14 01:13:51 PM
#12187   MSTX GO UP NEXT 0.65 sedrik 07/10/14 01:12:26 PM
#12186   Response: Thanks you for your email xxxxxxxx (my Rhodey Red 07/02/14 05:23:41 PM
#12185   Email are good but I do not think pray 07/02/14 09:49:52 AM
#12184   Management and officers have a bunch of one stocker25 07/01/14 02:08:13 AM
#12183   Ok. Thank's for the info. stocker25 07/01/14 02:03:25 AM
#12182   I hear ya! They had 3 events in hboss 06/30/14 11:23:24 PM
#12181   Hard to say other than speculation on my Rhodey Red 06/30/14 11:15:01 PM
#12180   What's your take on today's price action? And hboss 06/30/14 10:05:59 PM
#12179   Well it was more of a required 8k Rhodey Red 06/30/14 09:46:37 PM
#12178   Have you ever seen a company put out pray 06/30/14 07:18:16 PM
#12177   No. That was the essence of the data. Rhodey Red 06/30/14 06:00:34 PM
#12176   Do you think that we have to worry stocker25 06/30/14 10:43:07 AM
#12175   Thank's for the link. What do you think stocker25 06/30/14 10:41:35 AM
#12174   The full report: http://link.springer.com/article/10.1007%2Fs40268-014-0041-0/fu Rhodey Red 06/29/14 02:12:53 PM
#12173   http://www.bioportfolio.com/resources/pmarticle/984112/Differential-Effects-of-C Rhodey Red 06/29/14 02:10:51 PM
#12171   There is much tension today. Most orders neutral lecorb 06/26/14 01:36:56 PM
#12170   http://www.techsonian.com/sizzling-penny-stocks-north-american-palladium-nysemkt okaly 06/26/14 10:05:26 AM